Fused imidazolium derivatives
US6734203B2 · kind B2 · utility
8Cited by
3References
9Claims
0Family size
Inventors
Key dates
| Filing date | Jul 1, 2002 |
| Grant date | May 11, 2004 |
| Priority date | — |
| Expiry date | Jul 1, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to medicaments, particularly novel fused imidazolium derivatives useful for the treatment of cancers and novel synthetic intermediate compounds thereof.The novel imidazolium derivatives fused with an aryl or heteroaryl ring, characterized in that the 1- and/or 3-position is substituted by an alkyl group etc. having a substituent selected from the group consisting of —ORa, —SRa and the like, have excellent anti-tumor activity and low toxicity and are useful as anticancer agents having wide margins of safety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.